| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03347072 |
| P698 | PubMed publication ID | 21297383 |
| P2093 | author name string | M Maggi | |
| G Corona | |||
| E Baldi | |||
| P2860 | cites work | Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis | Q22306210 |
| Identification of a cell of origin for human prostate cancer | Q24594400 | ||
| Metabolic complications of androgen deprivation therapy for prostate cancer | Q24616159 | ||
| Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. | Q27824849 | ||
| Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
| Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) | Q29619860 | ||
| Effect of dutasteride on the risk of prostate cancer | Q30010961 | ||
| Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. | Q30308002 | ||
| Neuroendocrine cells in prostate cancer | Q30435708 | ||
| Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate | Q30471390 | ||
| A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma | Q33581390 | ||
| Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. | Q33602452 | ||
| A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis | Q33685619 | ||
| Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells | Q33694557 | ||
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. | Q33767866 | ||
| Complete androgen blockade for prostate cancer: what went wrong? | Q33935479 | ||
| EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). | Q33980606 | ||
| Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations | Q46451575 | ||
| Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. | Q46570705 | ||
| Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. | Q46776039 | ||
| Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies | Q46784184 | ||
| Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy | Q46875718 | ||
| Insulin sensitivity during combined androgen blockade for prostate cancer | Q46909972 | ||
| Circulating steroid hormones and the risk of prostate cancer | Q46910105 | ||
| Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. | Q51464753 | ||
| Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. | Q51499900 | ||
| Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. | Q52548115 | ||
| Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. | Q53429294 | ||
| Her-2-neu expression and progression toward androgen independence in human prostate cancer. | Q53800928 | ||
| Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer | Q53932137 | ||
| Androgen receptor mutations in prostate cancer. | Q54060047 | ||
| NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. | Q54707681 | ||
| Chemoprevention of Prostate Cancer | Q56483585 | ||
| Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition | Q56988228 | ||
| Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions | Q58229260 | ||
| Androgen Receptor: Good Guy or Bad Guy in Prostate Cancer Invasion? | Q63187482 | ||
| Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy | Q63359315 | ||
| Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide | Q68125383 | ||
| Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy | Q71235330 | ||
| Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls | Q71624041 | ||
| Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma | Q72751447 | ||
| Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer | Q72989706 | ||
| Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy | Q79446008 | ||
| Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer | Q80285083 | ||
| Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma | Q81100244 | ||
| Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality | Q81415275 | ||
| Pathology of benign prostatic hyperplasia | Q82570613 | ||
| Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 | Q83170866 | ||
| Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction | Q84464972 | ||
| TMPRSS2:ERG fusion gene and androgen-ablation therapy in prostate cancer | Q84497817 | ||
| Identification of late-onset hypogonadism in middle-aged and elderly men. | Q34022776 | ||
| A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium | Q34113217 | ||
| In vivo amplification of the androgen receptor gene and progression of human prostate cancer | Q34314274 | ||
| Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy | Q34332665 | ||
| Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities | Q34386388 | ||
| Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis | Q34502187 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| Persistent intraprostatic androgen concentrations after medical castration in healthy men. | Q34553305 | ||
| Prostate cancer risk in testosterone-treated men. | Q34582772 | ||
| Androgen deprivation therapy for prostate cancer: new concepts and concerns | Q34617845 | ||
| Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis | Q34768932 | ||
| Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth | Q34846764 | ||
| Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks | Q34960686 | ||
| Testosterone as a predictor of pathological stage in clinically localized prostate cancer | Q35758294 | ||
| Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. | Q35862931 | ||
| Androgen receptor cross-talk with cell signalling pathways | Q35934837 | ||
| Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma | Q36059488 | ||
| The human PC346 xenograft and cell line panel: a model system for prostate cancer progression | Q36368670 | ||
| Androgen receptor is a tumor suppressor and proliferator in prostate cancer | Q36858442 | ||
| Targeting the stromal androgen receptor in primary prostate tumors at earlier stages | Q36858449 | ||
| Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 | ||
| Cancer treatment-induced bone loss: pathophysiology and clinical perspectives | Q37096405 | ||
| Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. | Q37103095 | ||
| Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis | Q37113079 | ||
| Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. | Q37195196 | ||
| Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth | Q37196025 | ||
| The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction | Q37222063 | ||
| Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases | Q37396049 | ||
| 5alpha-reductase isozymes and androgen actions in the prostate | Q37403620 | ||
| Testosterone and prostate cancer: revisiting old paradigms | Q37450000 | ||
| Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. | Q37512391 | ||
| Targeting the PI3K/AKT pathway for the treatment of prostate cancer | Q37564760 | ||
| Molecular biology underlying the clinical heterogeneity of prostate cancer: an update | Q37566547 | ||
| Update on chemoprevention for prostate cancer. | Q37705965 | ||
| Abiraterone acetate for castration resistant prostate cancer | Q37708308 | ||
| Endocrine aspects of male sexual dysfunctions | Q37730212 | ||
| Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia | Q37732379 | ||
| Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails | Q37741773 | ||
| New agents and strategies for the hormonal treatment of castration-resistant prostate cancer | Q37762808 | ||
| Influence of sex hormones on cancer progression | Q37774171 | ||
| Testosterone, cardiovascular disease and the metabolic syndrome | Q37852330 | ||
| Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation | Q38350323 | ||
| Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial | Q38402163 | ||
| Testosterone replacement in prostate cancer survivors with hypogonadal symptoms | Q39295915 | ||
| Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation | Q39749979 | ||
| Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer | Q39750288 | ||
| Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less | Q39778629 | ||
| Hormonal predictors of prostate cancer | Q39804755 | ||
| Recent studies on the mechanism of action of testosterone | Q39868192 | ||
| Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer | Q39954334 | ||
| Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines | Q40180311 | ||
| The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype | Q40408878 | ||
| Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer. | Q40590766 | ||
| Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells | Q40631293 | ||
| Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype | Q40857949 | ||
| The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model | Q41054535 | ||
| Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process | Q41695916 | ||
| Changes in body composition during androgen deprivation therapy for prostate cancer | Q42166232 | ||
| Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells | Q42801295 | ||
| Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu | Q42945647 | ||
| Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke | Q43129404 | ||
| The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction | Q43242616 | ||
| A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy | Q43627769 | ||
| The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer | Q43732433 | ||
| Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. | Q44018378 | ||
| Long-term effects of androgen deprivation therapy in prostate cancer patients | Q44033179 | ||
| Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia | Q44290482 | ||
| Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy | Q44398102 | ||
| Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog | Q44480642 | ||
| Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer | Q44855302 | ||
| Mechanisms of androgen-refractory prostate cancer | Q45094999 | ||
| Testosterone replacement therapy after primary treatment for prostate cancer | Q45219185 | ||
| Endogenous sex hormones and metabolic syndrome in aging men. | Q45248596 | ||
| Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy | Q45269738 | ||
| Type 2 diabetes mellitus and testosterone: a meta-analysis study. | Q45921938 | ||
| Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. | Q45956742 | ||
| Testosterone replacement therapy following radical prostatectomy | Q46126585 | ||
| Absence of relationship between steroid hormone levels and prostate cancer tumor grade | Q46226739 | ||
| Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations | Q46388553 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 232-243 | |
| P577 | publication date | 2011-02-04 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Androgen regulation of prostate cancer: where are we now? | |
| P478 | volume | 34 |
| Q41207124 | 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia |
| Q85068495 | Abiraterone acetate: in metastatic castration-resistant prostate cancer |
| Q38738470 | Aging and sexual health: getting to the problem |
| Q39003600 | Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer |
| Q41548112 | Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness? |
| Q50662671 | Association between testosterone levels and the metabolic syndrome in adult men. |
| Q37618958 | Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. |
| Q38181426 | Benign prostatic hyperplasia: a new metabolic disease? |
| Q34449941 | Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R). |
| Q33767832 | Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo |
| Q44747186 | Ductal carcinoma of the prostate shows a different immunophenotype from high grade acinar cancer |
| Q38088550 | Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis |
| Q58279991 | Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study |
| Q38811041 | Endocrine control of benign prostatic hyperplasia. |
| Q47174327 | Estrogens and Body Weight Regulation in Men. |
| Q38235669 | Injectable testosterone undecanoate for the treatment of hypogonadism |
| Q38692706 | Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome |
| Q39192939 | MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor |
| Q26864777 | Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology |
| Q39870160 | Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry |
| Q37686901 | Quality of Life and Sexual Health in the Aging of PCa Survivors |
| Q36287950 | Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. |
| Q57582323 | Risk and Benefit of Androgen Deprivation Therapy in Prostate Cancer |
| Q37165019 | Risks and benefits of late onset hypogonadism treatment: an expert opinion |
| Q28554489 | Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors |
| Q58590625 | Sexual desire of French representative prostate cancer survivors 2 years after diagnosis (the VICAN survey) |
| Q38814349 | Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis |
| Q39302080 | Testosterone Replacement Therapy: Long-Term Safety and Efficacy |
| Q34332054 | Testosterone and cardiovascular risk |
| Q38848541 | Testosterone supplementation and body composition: results from a meta-analysis of observational studies. |
| Q50046284 | The safety of available treatments of male hypogonadism in organic and functional hypogonadism. |
| Q37148238 | The significance of galectin-3 as a new basal cell marker in prostate cancer |
| Q57278844 | Therapeutic implications of autophagy modulation in prostate cancer |
| Q37137452 | Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression |
Search more.